ARGX argenx SE

There are good reasons behind analyst's bullish views of this biotech stock.

European equities traded in the US as American depositary receipts were tracking slightly lower Thur

argenx (ENXTBR:ARGX) drew fresh attention after its Extraordinary General Meeting confirmed Thomas M. Brakel and Khurem Farooq as new non-executive directors, prompting investors to reassess how board composition might influence longer term decision making. argenx shares trade at €835.8 after a modest pullback, with the 30-day share price return down 3.29%. The 90-day move is up 6.91%, and the year-to-date share price return is 15.47%, while the 1-year total shareholder return sits at 34.37%...

argenx has delivered a striking share-price run over the past few years, which naturally puts the microscope on what investors are paying for its earnings today. With the stock coming off a strong multi‑year performance but some recent soft patches, the key issue is whether the current market price lines up with the profits the business is generating. Over the past 5 years, argenx shares have returned 228.2%, which raises the question of how much of that move can be explained by its earnings...

Stock Market Today: The Dow Jones index falls Wednesday after the Nasdaq set a new high Tuesday. Micron and Sandisk drop.

Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

On September 17, Halozyme (NASDAQ:HALO) priced $1.3 billion of convertible senior notes due 2033, an offering that grew from an originally planned $1.05 billion as demand came in. The notes carry a 1.50% coupon and convert into stock at $139.84 a share, a 27.5% premium to the $109.68 closing price that day. Investors who like […]

It's easy to be bullish about Argenx.

European equities traded in the US as American depositary receipts were tracking lower late Tuesday

This biotech innovator could be in only the early chapters of its success story.

Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.

Argenx stock has delivered very strong gains over the past five years, yet current valuation checks suggest investors are paying a premium rather than buying into an obvious bargain. A 209.7% return over 5 years points to a stock where expectations have risen sharply and pricing now embeds a lot of optimism. Positive Phase 3 data for Vyvgart Hytrulo in autoimmune myositis can support high growth expectations, while execution and clinical risk around expanding the immunology pipeline may...

argenx (ENXTBR:ARGX) is back in focus after reporting positive topline results from the ALKIVIA Phase 3 trial of VYVGART Hytrulo in autoimmune myositis, a rare muscle disease with limited targeted treatment options. argenx shares have reacted strongly around these developments, with a 30 day share price return of 17.54% and a 90 day share price return of 26.80%. The 1 year total shareholder return of 50.58% and 5 year total shareholder return of 209.69% suggest that momentum has been building...

argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment. FB102 is expected to be integrated into argenx's existing research and development programs focused on immunology. For readers who want more ideas in advanced immunology and related technologies, the next step is to explore 134 healthcare AI...

Argenx shares rally as UBS issues a bullish note. Here’s how high its analyst expects ARGX stock to fly in 2026.

European equities traded in the US as American depositary receipts were tracking lower late Wednesda

Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls

This biotech leader continues to rack up clinical successes.

European equities traded in the US as American depositary receipts started the week slightly lower l

argenx SE (NASDAQ:ARGX) delivered a clearly positive headline result from the Phase 3 ALKIVIA trial. VYVGART Hytrulo produced a 15.4-point mean advantage over placebo on the Total Improvement Score, or TIS, at Week 52 in the combined immune-mediated necrotizing myopathy and dermatomyositis population. The difference was statistically significant, with a p-value of 0.0011. The result […]

Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.

Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in […]

European equities traded in the US as American depositary receipts were tracking higher late Wednesd

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

Argenx's (ARGX) latest myositis data strengthened the outlook for efgartigimod, particularly in immu

argenx recently reported that its ALKIVIA Phase 3 trial of VYVGART Hytrulo in adults with autoimmune myositis met its primary endpoint, with patients showing statistically significant and clinically meaningful improvements in Total Improvement Score over 52 weeks versus placebo and a safety profile consistent with prior studies. A key insight is that this is the first Phase 3 study to show such benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies,...

Argenx stock surged Monday after its blockbuster autoimmune drug, Vyvgart, showed promise in patients with inflammatory diseases.

Argenx’s success in recent years was driven by Vyvgart. New trial data indicates the drug’s use could be expanded into treating other conditions.

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the